Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 9/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9903734 | 0.86 | FFAR4 (0.46) | SCDSCD5EPHX2 | |
| SCHEMBL2410139 | 0.85 | RBP4 (0.39) | KEAP1 | |
| SCHEMBL2410136 | 0.85 | RBP4 (0.39) | KEAP1 | |
| SCHEMBL4682397 | 0.84 | EPHX2 (0.46) | SCDEPHX2 | |
| SCHEMBL3976480 | 0.84 | SCD (0.56) | SCDSCD5 | |
| SCHEMBL9902292 | 0.84 | SCD (0.55) | SCDEPHX2 | |
| SCHEMBL6113438 | 0.83 | GPR119 (0.55) | — | |
| SCHEMBL2406476 | 0.83 | OPRK1 (0.43) | — | |
| SCHEMBL9902820 | 0.82 | EPHX2 (0.50) | SCDEPHX2 | |
| SCHEMBL23365170 | 0.81 | HRH1 (0.48) | SCDEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2331551-B1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | EVOTEC INTERNAT GMBH (DE) | 2016-06-29 | — | — | EP | disclosed |
| US-8486953-B2 | Thienopyrimidines for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| US-20120128686-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| CN-102186857-A | Thienopyrimidines for pharmaceutical compositions | BOEHRINGER INGELHEIM INT | 2011-09-14 | — | — | CN | disclosed |
| EP-2331551-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | Boehringer Ingelheim International GmbH (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010023181-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120128686-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DTYMK, CMPK1, PDXK | SCD 3916/4885KEAP1 1656/4885SCD5 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.